Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Thoracic 1

Conditions

Lymphoma, Follicular 2Asthma 2Bronchial Hyperreactivity 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Fluticasone-Salmeterol Drug Combination × Clear all
NCT00455923 2018-02-05

SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)

GlaxoSmithKline

Phase 4 Completed
100 enrolled 8 charts
LymphoidThoracic

Asthma, Lymphoma, Follicular, Bronchial Hyperreactivity

NCT00461500 2017-03-03

SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults

GlaxoSmithKline

Phase 4 Completed
81 enrolled 18 charts
Lymphoid

Asthma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡